References 591 & 690. Santana NO, Freitas RMC, Marcos VN, Chammas MC, Camargo RYA, Schmerling CK, et al. Diagnostic performance of thyroid ultrasound in Hurthle cell carcinomas. Arch Endocrinol Metab. 2019;63:300-305. https://doi. org/10.20945/2359-3997000000131. 691. Yip L, Sosa JA. Molecular-Directed Treatment of Differentiated Thyroid Cancer: Advances in Diagnosis and Treatment. JAMA Surg. 2016;151:663-670. https://doi.org/10.1001/jamasurg.2016.0825. 692. Valderrabano P, Eszlinger M, Stewardson P, Paschke R. Clinical value of molecular markers as diagnostic and prognostic tools to guide treatment of thyroid cancer. Clinical endocrinology. 2023. https://doi.org/10.1111/ cen.14882. 693. Silaghi CA, Lozovanu V, Georgescu CE, Georgescu RD, Susman S, Nasui BA, et al. Thyroseq v3, Afirma GSC, and microRNA Panels Versus Previous Molecular Tests in the Preoperative Diagnosis of Indeterminate Thyroid Nodules: A Systematic Review and Meta-Analysis. Frontiers in endocrinology. 2021;12:649522. https://doi.org/10.3389/ fendo.2021.649522. 694. Patel SG, Carty SE, Lee AJ. Molecular Testing for Thyroid Nodules Including Its Interpretation and Use in Clinical Practice. Annals of surgical oncology. 2021. https://doi.org/10.1245/s10434-021-10307-4. 695. de Koster EJ, Corver WE, de Geus-Oei LF, Oyen WJG, Ruano D, Schepers A, et al. A clinically applicable molecular classification of oncocytic cell thyroid nodules. Endocrine-related cancer. 2023;30. https://doi.org/10.1530/ERC-23-0047. 696. Nasr CE, Andrioli M, Endo M, Harrell RM, Livhits MJ, Osakwe I, et al. Real-World Performance of the Afirma Genomic Sequencing Classifier (GSC)-A Meta-analysis. The Journal of clinical endocrinology and metabolism. 2023;108:15261532. https://doi.org/10.1210/clinem/dgac688. 697. DiGennaro C, Vahdatzad V, Jalali MS, Toumi A, Watson T, Gazelle GS, et al. Assessing Bias and Limitations of Clinical Validation Studies of Molecular Diagnostic Tests for Indeterminate Thyroid Nodules: Systematic Review and MetaAnalysis. Thyroid. 2022;32:1144-1157. https://doi.org/10.1089/thy.2022.0269. 698. Dublin JC, Papazian M, Zan E, Oweity T, Sun W, Jacobson A, et al. Predictive Value of a Genomic Classifier in Indeterminate Thyroid Nodules Based on Nodule Size. JAMA otolaryngology - head & neck surgery. 2022;148:53-60. https://doi.org/10.1001/jamaoto.2021.3080. 699. Yip L, Gooding WE, Nikitski A, Wald AI, Carty SE, Karslioglu-French E, et al. Risk assessment for distant metastasis in differentiated thyroid cancer using molecular profiling: A matched case-control study. Cancer. 2021;127:1779-1787. https://doi.org/10.1002/cncr.33421. 700. Schumm MA, Shu ML, Hughes EG, Nikiforov YE, Nikiforova MN, Wald AI, et al. Prognostic Value of Preoperative Molecular Testing and Implications for Initial Surgical Management in Thyroid Nodules Harboring Suspected (Bethesda V) or Known (Bethesda VI) Papillary Thyroid Cancer. JAMA otolaryngology - head & neck surgery. 2023;149:735-742. https://doi.org/10.1001/jamaoto.2023.1494. 701. Filetti S, Durante C, Hartl DM, Leboulleux S, Locati LD, Newbold K, et al. ESMO Clinical Practice Guideline update on the use of systemic therapy in advanced thyroid cancer. Ann Oncol. 2022;33:674-684. https://doi.org/10.1016/j. annonc.2022.04.009. 702. Greaves M, Maley CC. Clonal evolution in cancer. Nature. 2012;481:306-313. https://doi.org/10.1038/nature10762. 703. Yates LR, Campbell PJ. Evolution of the cancer genome. Nat Rev Genet. 2012;13:795-806. https://doi.org/10.1038/ nrg3317. 704. Livhits MJ, Zhu CY, Kuo EJ, Nguyen DT, Kim J, Tseng CH, et al. Effectiveness of Molecular Testing Techniques for Diagnosis of Indeterminate Thyroid Nodules: A Randomized Clinical Trial. JAMA Oncol. 2021;7:70-77. https://doi. org/10.1001/jamaoncol.2020.5935. 705. Nikiforova MN, Lepe M, Tolino LA, Miller ME, Ohori NP, Wald AI, et al. Thyroid cytology smear slides: An untapped resource for ThyroSeq testing. Cancer cytopathology. 2021;129:33-42. https://doi.org/10.1002/cncy.22331. 706. Chen T, Gilfix BM, Rivera J, Sadeghi N, Richardson K, Hier MP, et al. The Role of the ThyroSeq v3 Molecular Test in the Surgical Management of Thyroid Nodules in the Canadian Public Health Care Setting. Thyroid. 2020;30:1280-1287. https://doi.org/10.1089/thy.2019.0539. 707. Suh HY, Choi H, Paeng JC, Cheon GJ, Chung JK, Kang KW. Comprehensive gene expression analysis for exploring the association between glucose metabolism and differentiation of thyroid cancer. BMC cancer. 2019;19:1260. https:// doi.org/10.1186/s12885-019-6482-7. 708. de Koster EJ, van Engen-van Grunsven ACH, Bussink J, Frielink C, de Geus-Oei LF, Kusters B, et al. [(18)F]FDG Uptake and Expression of Immunohistochemical Markers Related to Glycolysis, Hypoxia, and Proliferation in Indeterminate Thyroid Nodules. Mol Imaging Biol. 2023;25:483-494. https://doi.org/10.1007/s11307-022-01776-4. 709. Quaytman JA, Nikiforov YE, Nikiforova MN, Morariu E. Clinicopathologic features of thyroid nodules with PTEN mutations on preoperative testing. Endocrine-related cancer. 2022;29:513-520. https://doi.org/10.1530/ERC-220061. 710. Juhlin CC. On the Chopping Block: Overview of DICER1 Mutations in Endocrine and Neuroendocrine Neoplasms. Surg Pathol Clin. 2023;16:107-118. https://doi.org/10.1016/j.path.2022.09.010.
RkJQdWJsaXNoZXIy MTk4NDMw